Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Dermatologic Manifestations of Sarcoidosis

  • Author: Joseph F Merola, MD, MMSc; Chief Editor: Dirk M Elston, MD  more...
 
Updated: Nov 20, 2015
 

Overview

Dermatologic manifestations are seen in 25% of patients with sarcoidosis. They usually accompany systemic involvement, but in some cases they may be the only manifestations of the disease. Sarcoidosis is characterized by noncaseating epithelioid granulomas that may affect any organ system.

Although Jonathan Hutchinson described the first case in 1869, the etiology of the disease is still unknown. The disease most commonly involves granuloma formation in the lungs, with 90-95% of patients having some pulmonary involvement. Other commonly involved organ systems include the lymph nodes (especially the intrathoracic nodes), the skin, the eyes, the liver, the heart, and the nervous, musculoskeletal, renal, and endocrine systems.

Next

Physical Examination

Cutaneous involvement is classified as either "specific" or "nonspecific". Histopathologically, specific lesions manifest as noncaseating granulomas, whereas nonspecific lesions do not reveal granulomas on histopathologic examination. Erythema nodosum (EN) (shown below) is the main nonspecific cutaneous disease. Lupus pernio, maculopapular, nodular, scar, plaque, angiolupoid, ichthyosiform, lichenoid, annular, verrucous, psoriasiform, and ulcerative lesions and subcutaneous nodules are examples of specific cutaneous disease.

Erythema nodosum. Erythema nodosum.

Blau syndrome and early-onset sarcoidosis represent familial and sporadic forms of pediatric granulomatous autoinflammatory disease caused by mutations in the NOD2 gene. Clinical onset is usually early in life, with noncaseating granulomas affecting the skin, joints, and uveal tract.[1, 2]

Erythema nodosum

EN is a hypersensitivity reaction resulting from exposure to a variety of infectious agents (especially recent streptococcal infection), drugs (including oral contraceptives), or systemic inflammatory disorders (eg, sarcoidosis, inflammatory bowel disease). EN is usually an acute, self-limiting process and rarely requires treatment. Recurrences are uncommon. Tender, erythematous nodules are usually present on the extremities, most commonly on the anterior surface of the tibia. Fever, arthralgia, and malaise may occur. EN is more common in European, especially Scandinavian, women of childbearing age than in other people.

Loefgren syndrome

Löfgren syndrome is classically described as a triad of EN, polyarthritis, and hilar adenopathy. The adenopathy may be unilateral or bilateral hilar and/or right paratracheal lymphadenopathy. Other symptoms include anterior uveitis, fever, ankle periarthritis, arthralgias, and pulmonary involvement.

Löfgren syndrome is usually an acute disease with an excellent prognosis, typically resolving spontaneously from 6-8 weeks to up to 2 years after onset. Pulmonologists, ophthalmologists, and rheumatologists often define this syndrome differently, describing varying combinations of arthritis, arthralgia, uveitis, EN, hilar adenopathy, and/or other clinical findings. (See the image below.)

Lupus pernio

Lupus pernio, first described by Besnier in 1889, is a striking manifestation of sarcoidal skin lesions. Lupus pernio is characterized by red to purple or violaceous, indurated plaques and nodules that usually affect the nose, cheeks, ears, and lips, but it can appear on the dorsa of the hands, and on the fingers, toes, and forehead. (See the images below.)

Lupus pernio with nodules on the nasal tip and sid Lupus pernio with nodules on the nasal tip and sidewall.
Cutaneous sarcoidosis. Violaceous papules or nodul Cutaneous sarcoidosis. Violaceous papules or nodules of lupus pernio.

Lupus pernio is usually more common in black women with long-standing systemic, usually pulmonary, sarcoidosis than in other people. It is also commonly seen with chronic uveitis and bone cysts. The course is usually chronic, may be more recalcitrant to treatment, and may result in severe cosmetic disfigurement. Lupus pernio, especially involving the nasal rim, has been associated with granulomatous involvement of the upper respiratory tract (50%) and lungs (75%). Additionally, it is associated with a higher frequency of ocular involvement, bone cyst formation, and lymphadenopathy or organomegaly.[3]

Macular sarcoidosis

Macular or papular sarcoidosis is the most common lesion seen in cutaneous sarcoidosis, especially in black women. Granulomatous acne rosacea may mimic sarcoidosis clinically and histopathologically. Usually, lesions are asymptomatic, red-brown macules and papules commonly involving the face, the periorbital areas, the nasolabial folds, and/or the extensor surfaces. Lesions usually resolve without scarring, although scarring may occur. These lesions may also occur in acute sarcoidosis. (See the image below.)

Periocular papules and plaques. Periocular papules and plaques.

The use of dermoscopy to aid in the clinical diagnosis of macular and plaque-type sarcoidosis has been reported, with findings of "translucent yellow to orange globular-like or structureless areas associated with linear vessels" and being associated with granulomatous skin disease, including cutaneous sarcoid.[4] Widespread atrophic lesions with elastolysis have been reported, and widespread lichenoid lesions may resemble erythroderma.[5, 6]

Plaque sarcoidosis

Plaque sarcoidosis is characterized by round to oval, red-brown to purple, infiltrated plaques; the center of the plaque may be atrophic (see the image below). Some plaques may even appear scaly and can be confused with lesions of psoriasis or lichen planus. Dermoscopy may aid in the clinical diagnosis, as noted above.

Plaque sarcoidosis. Plaque sarcoidosis.

The lesions most commonly occur on the extremities, face, scalp, back, and buttocks, and they may have an annular appearance (see the image below). The distribution is usually symmetrical. Angiolupoid sarcoidosis is a subtype that has a similar appearance but has large, telangiectatic vessels in addition to the characteristics mentioned above. This form of cutaneous involvement is usually chronic; most patients have the disease for more than 2 years. Lesions can heal with scarring, and, if plaques involve the scalp, they may lead to alopecia. Patients with plaque lesions usually have more severe systemic involvement.

Annular sarcoidosis. Annular sarcoidosis.

Subcutaneous nodular sarcoidosis

Subcutaneous nodular sarcoidosis is also called Darier-Roussy sarcoidosis. Lesions are usually nontender, firm, oval, flesh-colored or violaceous nodules that are 0.5-2 cm in diameter. They are commonly found on the extremities or trunk. These lesions usually appear in the beginning of the disease. Patients with these lesions often have nonsevere systemic disease. In some patients, the nodules resolve spontaneously.[7, 8]

Other lesions

Sarcoidosis is called the "great imitator" because it can have almost any morphology.[9] Other rare lesions of cutaneous sarcoidosis are ichthyosiform,[10] lichenoid, vasculitic,[11] psoriasiform, erythrodermic, verrucous, papillomatous, and ulcerative lesions. (See the image below.)

Erythematous papules on the knee. Erythematous papules on the knee.

Scar and tattoo infiltration

Infiltration of scars may occur (see the image below). Scars from previous trauma, surgery, venipuncture, or tattoo may become infiltrated and show a red or purple color. These lesions may be tender.

Sarcoidosis with infiltration of a scar. Sarcoidosis with infiltration of a scar.

The development of sarcoidal lesions within tattoos has been well documented, although hypersensitivity granulomatous reactions to tattoo pigment need to considered in the differential diagnosis and should be considered in the context of the overall clinical presentation of the sarcoid patient. Specific tattoo pigment colors may be targeted more than others, even within the same patient with a multicolored tattoo.[12]

Previous
Next

Differential Diagnosis

Dermatologic conditions to consider in the differential diagnosis of sarcoidosis include the following:

  • Cutaneous tuberculosis
  • Drug eruptions
  • Granuloma annulare
  • Granuloma faciale
  • Lamellar ichthyosis
  • Leprosy
  • Lichen planus
  • Discoid lupus erythematosus
  • Subacute cutaneous lupus erythematosus
  • Lymphocytoma cutis
  • Necrobiosis lipoidica
  • Plaque psoriasis
  • Syphilis
  • Tinea corporis

B-cell lymphoma, foreign body reaction (including hypersensitivity granulomatous reaction to tattoo pigment), and lichen planopilaris should also be considered in the differential diagnosis.

Previous
Next

Kveim-Siltzbach Test and Tuberculin Skin Test

Kveim-Siltzbach test

The Kveim test is the most specific test for sarcoidosis. It is not commonly available, nor commonly used, because of difficulty in obtaining a validated antigen source, as well as a fear of transmitting infection. The Kveim test involves intradermal injection of tissue from the spleen or the lymph node of a patient with sarcoidosis. A biopsy sample is obtained from the area 4-6 weeks after injection and is histologically examined for noncaseating granuloma formation, which, if found, indicates a positive result.

Tuberculin skin test

Regarding the tuberculin skin test, patients with sarcoidosis have impaired delayed-type immune reactions. Two thirds of patients with systemic sarcoidosis have cutaneous anergy to the tuberculin and other skin tests. It is not known if cutaneous anergy is frequent in patients with cutaneous lesions of sarcoidosis with little or no systemic involvement.

Previous
Next

Biopsy

The skin is the most easily accessible tissue for biopsy and is extremely helpful in supporting the diagnosis of sarcoidosis. Biopsy of erythema nodosum, however, is less helpful as it is not specific for sarcoidosis. Biopsy specimens need to be sent for histologic examination, and staining may need to be performed to rule out infectious causes of granuloma formation, including mycobacterial and deep fungal infections. Tissue culture may be appropriate in some clinical settings, especially if fungal or atypical mycobacterial infections are suspected.

Previous
Next

Histologic Findings

Typical sarcoid lesions are characterized as “naked,” noncaseating granulomas. Granulomas are referred to as naked because they only have a sparse lymphocytic infiltrate at the margins of granulomas. The granulomas are generally circumscribed and composed of epithelioid cells with little or no necrosis. Fibrosis, if present, usually starts at the periphery and advances toward the center. Granulomas are usually in the superficial dermis, but they may involve the thickness of the dermis and extend to the subcutaneous tissue. (See the image below.)

Histopathologic features of sarcoidosis showing th Histopathologic features of sarcoidosis showing the hallmark noncaseating granulomas.

Islands of epithelioid cells may contain a few Langhans giant cells. Giant cells may contain asteroid or Schaumann bodies. Asteroid bodies are star-shaped eosinophilic structures. Schaumann bodies are round or oval, laminated structures that are usually calcified at the periphery.

Previous
Next

Pharmacologic Therapy

The need for medical therapy varies based on the symptoms and the organ systems involved in each patient. Oral corticosteroids are usually the treatment of choice for patients with hypercalcemia and for those with serious end-organ involvement, such as symptomatic stage II and all stage III pulmonary disease, as well as for patients with neurologic, cardiac, or ocular involvement. As opposed to the more severe systemic involvement requiring oral therapy, Löfgren syndrome is usually an acute process that is self-limited and that resolves without immunosuppressive treatment in weeks. Symptomatic relief can be obtained using nonsteroidal anti-inflammatory drugs (NSAIDs) or relatively low doses of corticosteroids.

Limited, nondisfiguring cutaneous involvement may be treated with topical or intralesional corticosteroids. Intralesional injections of 2-10 mg/mL[13] of triamcinolone acetonide can be used at monthly intervals. More chronic skin lesions, such as plaques or lupus pernio, require more aggressive therapy because they can lead to permanent scarring.

If intralesional corticosteroids are not effective, other standard therapies include systemic corticosteroids, low-dose oral or subcutaneous methotrexate,[14, 15, 16] or antimalarials (hydroxychloroquine[17] and chloroquine).[18] Anti–tumor necrosis factor-alpha therapy and other biological agents represent promising options for patients with recalcitrant or disfiguring disease.[13, 19, 20, 21, 22]

Other agents that have been used to treat cutaneous sarcoidosis include the following:

One case report describes remission of sarcoidosis after the patient was placed on an angiotensin-converting enzyme (ACE) inhibitor.[35] Another report describes improvement in two cases using photodynamic therapy with methyl aminolevulinate (Metvix).[36]  Intralesional 5-fluoruracil has been used successfully.[37]

Previous
Next

Radiation and Surgical Treatment

In terms of nonpharmacologic therapy, radiation has been used in cases of treatment-resistant cutaneous lesions.[38]

Surgical resection of smaller, severely disfiguring and recalcitrant lesions may be attempted. The risk of lesion recurrence and hypertrophic and keloidal scarring does exist. Laser surgery using carbon dioxide[39] and pulsed dye laser has also been used in the treatment of disfiguring skin plaques and lupus pernio.[13]

Previous
Next

Additional Treatment Considerations

Inpatient care

Inpatient care is rarely needed for patients with cutaneous disease. However, in patients with respiratory insufficiency, hospitalization may be needed. Complications of systemic immunosuppressive therapy, namely severe infection, may result in hospitalization.

Consultations

Early involvement of other clinicians, such as an ophthalmologist, an internist, a rheumatologist, and a pulmonologist, for monitoring other organ systems that may be involved is recommended. Choice of consultation specialist is driven by symptoms and end-organ of involvement.

Long-term monitoring

Follow-up care should be frequent for the first 2 years after diagnosis. Patients with stage I disease can receive follow-up care twice yearly, whereas patients with more advanced lung disease should be seen more frequently. All patients should be monitored for at least 3 years after discontinuation of therapy.

During follow-up care, patients should have a history with a review of systems and should undergo physical examination, chest radiography, and pulmonary function tests to evaluate for active or insidiously progressive disease. A baseline electrocardiogram is of use to assess for cardiac involvement and for future comparison if symptoms develop. Baseline laboratory examination may include calcium and vitamin D levels as calcium dysregulation with hypercalcemia may occur. In general, an angiotensin-converting enzyme (ACE) level has limited usefulness as a diagnostic test for sarcoidosis.

Ophthalmologic assessment is needed initially—generally annually in all patients and more frequently in those with ocular involvement. Therapeutic use of hydroxychloroquine (Plaquenil) may also warrant more frequent, detailed ophthalmologic examinations.

A large review by Ji et al of the Swedish Hospital Registry noted an elevated risk of skin cancer (especially squamous cell carcinoma), non-Hodgkin lymphoma, and leukemia in hospitalized patients with sarcoidosis, extending beyond the first year after hospitalization. Therefore, close follow up for malignancies is recommended.[40]

Previous
 
Contributor Information and Disclosures
Author

Joseph F Merola, MD, MMSc Assistant Professor of Dermatology, Harvard Medical School; Director of Clinical Trials for Dermatology, Co-Director, Center for Skin and Related Musculoskeletal Diseases, Department of Dermatology and Department of Medicine, Division of Rheumatology, Associate Program Director, Combined Medicine-Dermatology Residency Program, Brigham and Women's Hospital

Joseph F Merola, MD, MMSc is a member of the following medical societies: American Academy of Dermatology, American College of Rheumatology, Massachusetts Medical Society, Medical Dermatology Society, Rheumatologic Dermatology Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: AbbVie; Biogen IDEC; Eli Lilly; Janssen; Momenta<br/>Serve(d) as a speaker or a member of a speakers bureau for: AbbVie; Eli Lilly<br/>Received grant/research funds from Biogen IDEC for investigation; Received honoraria from Amgen for investigation; Received honoraria from Amgen for review panel membership; Received honoraria from Eli Lilly for review panel membership; Received honoraria from Novartis for review panel membership; Received honoraria from Pfizer for investigation. .

Coauthor(s)

Jeffrey P Callen, MD Professor of Medicine (Dermatology), Chief, Division of Dermatology, University of Louisville School of Medicine

Jeffrey P Callen, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, American College of Rheumatology

Disclosure: Received income in an amount equal to or greater than $250 from: XOMA; Biogen/IDEC; Novartis; Janssen Biotech, Abbvie, CSL pharma<br/>Received honoraria from UpToDate for author/editor; Received honoraria from JAMA Dermatology for associate editor and intermittent author; Received royalty from Elsevier for book author/editor; Received dividends from trust accounts, but I do not control these accounts, and have directed our managers to divest pharmaceutical stocks as is fiscally prudent from Stock holdings in various trust accounts include some pharmaceutical companies and device makers for i inherited these trust accounts; for: Celgene; Pfizer; 3M; Johnson and Johnson; Merck; Abbott Laboratories; AbbVie; Procter and Gamble; Amgen.

Specialty Editor Board

Michael J Wells, MD, FAAD Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine

Michael J Wells, MD, FAAD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, Texas Medical Association

Disclosure: Nothing to disclose.

Jeffrey Meffert, MD Associate Clinical Professor of Dermatology, University of Texas School of Medicine at San Antonio

Jeffrey Meffert, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, Association of Military Dermatologists, Texas Dermatological Society

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

Ponciano D Cruz, Jr, MD Professor and Vice-Chair, Paul R Bergstresser Chair, Department of Dermatology, University of Texas Southwestern Medical Center

Ponciano D Cruz, Jr, MD is a member of the following medical societies: Texas Medical Association

Disclosure: Received consulting fee from RCTS for independent contractor; Received honoraria from Mary Kay Cosmetics for consulting; Received grant/research funds from Galderma for principal investigator.

Acknowledgements

Karen Podlipsky Gould, MD Physician, Private Practice

Karen Podlipsky Gould, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

References
  1. Caso F, Costa L, Rigante D, et al. Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis. Autoimmun Rev. 2014 Aug 23. [Medline].

  2. Caso F, Galozzi P, Costa L, Sfriso P, Cantarini L, Punzi L. Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's disease. RMD Open. 2015. 1 (1):e000097. [Medline].

  3. Hunt RD, Gonzalez ME, Robinson M, Meehan SA, Franks AG Jr. Ulcerative sarcoidosis. Dermatol Online J. 2012 Dec 15. 18(12):29. [Medline].

  4. Pellicano R, Tiodorovic-Zivkovic D, Gourhant JY, Catricala C, Ferrara G, Caldarola G. Dermoscopy of cutaneous sarcoidosis. Dermatology. 2010 Aug. 221(1):51-4. [Medline].

  5. Fancher W, Braniecki M, Guzman G, Groth J, Krunic A. Disseminated atrophic sarcoidosis with elastophagocytosis and elastic tissue loss. Br J Dermatol. 2014 Sep 16. [Medline].

  6. Nishizawa A, Igawa K, Teraki H, Yokozeki H. Diffuse disseminated lichenoid-type cutaneous sarcoidosis mimicking erythroderma. Int J Dermatol. 2014 Aug. 53(8):e369-70. [Medline].

  7. Jorizzo JL, Koufman JA, Thompson JN, White WL, Shar GG, Schreiner DJ. Sarcoidosis of the upper respiratory tract in patients with nasal rim lesions: a pilot study. J Am Acad Dermatol. 1990 Mar. 22(3):439-43. [Medline].

  8. Marcoval J, Maña J, Moreno A, Peyri J. Subcutaneous sarcoidosis--clinicopathological study of 10 cases. Br J Dermatol. 2005 Oct. 153(4):790-4. [Medline].

  9. Ahmed I, Harshad SR. Subcutaneous sarcoidosis: is it a specific subset of cutaneous sarcoidosis frequently associated with systemic disease?. J Am Acad Dermatol. 2006 Jan. 54(1):55-60. [Medline].

  10. Tchernev G. Cutaneous sarcoidosis: the "great imitator": etiopathogenesis, morphology, differential diagnosis, and clinical management. Am J Clin Dermatol. 2006. 7(6):375-82. [Medline].

  11. Cather JC, Cohen PR. Ichthyosiform sarcoidosis. J Am Acad Dermatol. 1999 May. 40(5 Pt 2):862-5. [Medline].

  12. Antonovich DD, Callen JP. Development of sarcoidosis in cosmetic tattoos. Arch Dermatol. 2005 Jul. 141(7):869-72. [Medline].

  13. Garcia-Porrua C, Gonzalez-Gay MA, Garcia-Pais MJ, Blanco R. Cutaneous vasculitis: an unusual presentation of sarcoidosis in adulthood. Scand J Rheumatol. 1998. 27(1):80-2. [Medline].

  14. Doherty CB, Rosen T. Evidence-based therapy for cutaneous sarcoidosis. Drugs. 2008. 68(10):1361-83. [Medline].

  15. Gedalia A, Molina JF, Ellis GS Jr, Galen W, Moore C, Espinoza LR. Low-dose methotrexate therapy for childhood sarcoidosis. J Pediatr. 1997 Jan. 130(1):25-9. [Medline].

  16. Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med. 1995 Apr 24. 155(8):846-51. [Medline].

  17. Webster GF, Razsi LK, Sanchez M, Shupack JL. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol. 1991 Mar. 24(3):451-4. [Medline].

  18. Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol. 1990 Sep. 23(3 Pt 1):487-9. [Medline].

  19. Baughman RP, Lower EE. Steroid-sparing alternative treatments for sarcoidosis. Clin Chest Med. 1997 Dec. 18(4):853-64. [Medline].

  20. Stagaki E, Mountford WK, Lackland DT, Judson MA. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest. 2009 Feb. 135(2):468-76. [Medline].

  21. Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013 May. 68(5):765-73. [Medline].

  22. Judson MA, Baughman RP, Costabel U, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J. 2014 Jul 17. [Medline].

  23. Tu J, Chan J. Cutaneous sarcoidosis and infliximab: evidence for efficacy in refractory disease. Australas J Dermatol. 2013 May 8. [Medline].

  24. Philips MA, Lynch J, Azmi FH. Ulcerative cutaneous sarcoidosis responding to adalimumab. J Am Acad Dermatol. 2005 Nov. 53(5):917. [Medline].

  25. Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013 May. 68(5):765-73. [Medline].

  26. Kiorpelidou D, Gaitanis G, Zioga A, Bassukas ID. Short course of infliximab for disfiguring lupus pernio. Eur J Dermatol. 2008 Nov-Dec. 18(6):727-9. [Medline].

  27. Kataria YP. Chlorambucil in sarcoidosis. Chest. 1980 Jul. 78(1):36-43. [Medline].

  28. Waldinger TP, Ellis CN, Quint K, Voorhees JJ. Treatment of cutaneous sarcoidosis with isotretinoin. Arch Dermatol. 1983 Dec. 119(12):1003-5. [Medline].

  29. Brechtel B, Haas N, Henz BM, Kolde G. Allopurinol: a therapeutic alternative for disseminated cutaneous sarcoidosis. Br J Dermatol. 1996 Aug. 135(2):307-9. [Medline].

  30. Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol. 2001 Jan. 137(1):69-73. [Medline].

  31. Heffernan MP, Anadkat MJ. Recalcitrant cutaneous sarcoidosis responding to infliximab. Arch Dermatol. 2005 Jul. 141(7):910-1. [Medline].

  32. Carlesimo M, Giustini S, Rossi A, Bonaccorsi P, Calvieri S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol. 1995 May. 32(5 Pt 2):866-9. [Medline].

  33. Kalajian AH, Van Meter JR, Callen JP. Sarcoidal anemia and leukopenia treated with methotrexate and mycophenolate mofetil. Arch Dermatol. 2009 Aug. 145(8):905-9. [Medline].

  34. Kouba DJ, Mimouni D, Rencic A, Nousari HC. Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol. 2003 Jan. 148(1):147-8. [Medline].

  35. Lee JB, Koblenzer PS. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. J Am Acad Dermatol. 1998 Nov. 39(5 Pt 2):835-8. [Medline].

  36. Rousseau L, Beylot-Barry M, Doutre MS, Beylot C. Cutaneous sarcoidosis successfully treated with low doses of thalidomide. Arch Dermatol. 1998 Aug. 134(8):1045-6. [Medline].

  37. Gharavi N, Diehl J, Soriano T. Cutaneous Sarcoidosis Successfully Treated With Intralesional 5-Fluorouracil. Dermatol Surg. 2015 Sep. 41 (9):1082-5. [Medline].

  38. Fazzi P. Pharmacotherapeutic management of pulmonary sarcoidosis. Am J Respir Med. 2003. 2(4):311-20. [Medline].

  39. Kaura V, Kaura SH, Kaura CS. ACE Inhibitor in the treatment of cutaneous and lymphatic sarcoidosis. Am J Clin Dermatol. 2007. 8(3):183-6. [Medline].

  40. Wilsmann-Theis D, Bieber T, Novak N. Photodynamic therapy as an alternative treatment for cutaneous sarcoidosis. Dermatology. 2008. 217(4):343-6. [Medline].

 
Previous
Next
 
Erythema nodosum.
Bilateral hilar lymphadenopathy.
Stage III pulmonary disease with pulmonary infiltrates.
Periocular papules and plaques.
Plaque sarcoidosis.
Erythematous papules on the knee.
Lupus pernio with nodules on the nasal tip and sidewall.
Annular sarcoidosis.
Sarcoidosis with infiltration of a scar.
Histopathologic features of sarcoidosis showing the hallmark noncaseating granulomas.
Cutaneous sarcoidosis. Violaceous papules or nodules of lupus pernio.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.